← All trials
NCT05650918
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2021
- Primary completion
- Oct 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- Dec 14, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.